Summary
Introduction The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC) patients. Methods Eligibility criteria included recurrent/metastatic NSCLC, having received 2 prior systemic regimens, and performance status 0–2. Patients took vorinostat 400 mg PO daily days 1–14 and bortezomib 1.3 mg/m2 IV day 1, 4, 8 and 11 in a 21-day cycle. Primary endpoint was 3-month progression free survival (3m-PFS), with a goal of at least 40 % of patients being free of progression at that time point. This study followed a two-stage minimax design. Results Eighteen patients were enrolled in the first stage. All patients had two prior lines of treatment. Patients received a median of two treatment cycles (range: 1–6) on study. There were no anti-tumor responses; stable disease was observed in 5 patients (27.8 %). Median PFS was 1.5 months, 3m-PFS rate 11.1 %, and median overall survival 4.7 months. The most common grade 3/4 toxicities were thrombocytopenia and fatigue. Two patients who had baseline taxane-related grade 1 peripheral neuropathy developed grade 3 neuropathy. The study was closed at its first interim analysis for lack of efficacy. Conclusions Bortezomib and vorinostat displayed minimal anti-tumor activity as third-line therapy in NSCLC. We do not recommend this regimen for further investigation in unselected patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boyer M, Horwood K, Pavlakis N et al (2012) Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol 8:248–254
Komatsu N, Kawamata N, Takeuchi S et al (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15:187–191
Traynor AM, Dubey S, Eickhoff JC et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4:522–526
Schenkein DP (2005) Preclinical data with bortezomib in lung cancer. Clin Lung Cancer 7(Suppl 2):S49–S55
Davies AM, Lara PN Jr, Mack PC, Gandara DR (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13:s4647–s4651
Denlinger CE, Rundall BK, Jones DR (2004) Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128:740–748
Schelman W, Kolesar J, Schell K et al (2007) A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:Abstr. 3573
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246
Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019
Ramalingam SS, Maitland ML, Frankel P et al (2010) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56–62
Scagliotti GV, Germonpre P, Bosquee L et al (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68:420–426
Jones DR, Moskaluk CA, Gillenwater HH et al (2012) Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol 7:1683–1690
Acknowledgement
This study was supported in part by Millennium, Merck, and the University of Wisconsin Carbone Cancer Center (P30 CA014520).
Ethical standard
The conduction of this study complies with the current laws of the United States.
Conflict of interest
All authors—Millennium’s and Merck’s grants to institutions.
KyungMann Kim—Consultant (Scientific advisory committee for the house dust mite autoimmunity tablet program).
Jill Kolesar—Wisconsin Alumni Research Foundation (Patent to institution); Helix Diagnostics (Patent royalties); McGraw Hill (Textbook royalties); Chequemegon Pharmacotherapy Partners (Managing partner); Thomsen Reuters (Consultant); ACCP Research Institute and ISOPP (Travels/Meetings).
Anne M Traynor—Celgene (Consultant, one time in June 2012); Novartis, Novelos, Bayer, BMS, Pfizer (Grants/Pending grants).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoang, T., Campbell, T.C., Zhang, C. et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs 32, 195–199 (2014). https://doi.org/10.1007/s10637-013-9980-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-013-9980-5